Small Cell Transformation in Pancreatic Metastasis from EGFR-Mutated Lung Adenocarcinoma Following TKI
10.15279/kpba.2025.30.2.76
- Author:
Wootaek SEO,
1
;
Hyeon-Gi KIM
;
Hee-Eon LIM
;
Kwangrok JUNG
;
Jong-Chan LEE
;
Jin-Hyeok HWANG
;
Jaihwan KIM
Author Information
1. Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
- Publication Type:Case Report
- From:Korean Journal of Pancreas and Biliary Tract
2025;30(2):76-80
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Lazertinib is an oral, third-generation, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) for the treatment of non-small cell lung cancer (NSCLC). This case report presents a rare instance of small cell carcinoma transformation in pancreatic metastasis in a patient with EGFR-mutated NSCLC undergoing treatment with lazertinib. Small cell carcinoma transformation indicates a mechanism of treatment resistance, and tissue biopsy is essential to confirm this. When isolated progression of a lesion is suspected during TKI therapy in EGFR-mutated NSCLC, histological evaluation is necessary to confirm the transformation for the treatment strategy.
